Close Menu

NEW YORK (GenomeWeb) – Enigma Diagnostics, a UK firm currently in liquidation, announced today it is selling intellectual property underlying its point-of-care molecular diagnostics platform.

The technology — which was originally created at the UK Ministry of Defence Science and Technology Laboratory — was developed by Enigma into an easy-to-use molecular diagnostics process which the firm noted has been tested in hospitals in Europe and China with accuracy rates in excess of 90 percent. It has also received £140M million ($174 million) in investments to date.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

May
22

This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal Digital PCR with the Naica System from Stilla Technologies.